Nevertheless, it has become apparent that the driving forces for cancer-associated macropinocytosis may be more diversified than expected since independent studies revealed that macropinocytosis could be enhanced by KRAS, HRAS, EGFR activation 28, galectin-3 27, loss of PTEN 29, Src activation 30, etc. This evidence concerns the gene KRAS and cancer.